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Abstract
Background: Polymorphisms are associated with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary
thromboembolism (PTE), but no polymorphism specific to CTEPH but not PTE has yet been reported. Fibrin resistance is
associated with CTEPH, but the mechanism has not been elucidated.
Methods: Polymorphisms were analyzed in 101 CTEPH subjects, 102 PTE subjects and 108 healthy controls by Massarray or
restriction fragment length polymorphism (RFLP). Plasmin-mediated cleavage of fibrin was characterized in 69 subjects (29
with CTEPH, 21 with PTE and 19 controls).
Results: Genotype frequencies and allele frequencies of fibrinogen Aa Thr312Ala were significantly higher in CTEPH subjects
than in controls and PTE subjects, while there was no difference between PTE subjects and controls. The odd ratio (OR
2.037) and 95% confidence interval (95% CI, 1.262–3.289) showed that Thr312Ala polymorphism was a risk factor for CTEPH
but not PTE. Fibrin from CTEPH subjects was more resistant to lysis than that from PTE subjects and controls. Fibrin
resistance was significantly different between Aa Thr312Ala (A/G) genotypes within CTEPH subjects, and the fibrin with GG
genotype was more resistant than that with AA and AG genotype.
Conclusions: Fibrinogen Aa Thr312Ala (A/G) polymorphism was associated with CTEPH, but not PTE, suggesting that the
fibrinogen Aa Thr312Ala polymorphism may act as a potential biomarker in identifying CTEPH from PTE. GG genotype
polymorphism contributes to CTEPH through increasing fibrin resistance, implying that PTE subjects with fibrinogen Aa GG
genotype may need long-term anticoagulation therapy.
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Introduction
Chronic thromboembolic pulmonary hypertension (CTEPH),
characterized by chronic and organized thromboembolic obstruc-
tion of the main, lobar and/or segmental pulmonary arteries, is a
significant health threat [1,2,3]. While it is currently hypothesized
that CTEPH is caused by unresolved thromboembolus of acute
pulmonary thromboembolism (PTE) and increase in pulmonary
vascular resistance (PVR), the pathogenesis of CTEPH remains
unclear [3,4]. In clinical practice, thromboembolus in most PTE
subjects is dissolved within several weeks to several months after
treatments such as fibrinolysis [5], however, a minority of patients
failed to properly resolve thromboembolus [6]. Evidence suggests
that CTEPH is triggered by failure to dissolve PTE [7,8].
Fibrin derived from CTEPH subjects is more resistant to lysis by
proteases (plasmin) than that derived from healthy controls in
in vitro experiments [9]. Interestingly, fibrin resistance was also
reported in subjects with pulmonary hypertension (PH) other than
thromboembolic [10]. Minor resistance of fibrin was also observed
in subjects with prior pulmonary embolism and no evidence of
pulmonary hypertension [10]. These data indicate that fibrin
resistance may play an important role in the development of
CTEPH.
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Fibrin resistance may be affected by factors such as fibrin
stabilization or fibrinolysis. Fibrinogen polymorphisms are associ-
ated with thrombotic diseases such as myocardial infarction and
stroke [11]. Among most common inherited thrombotic risk factor
abnormalities, such as antithrombin, protein C, protein S, factor V
and factor II mutations [12], there has been no frequency
difference to date between CTEPH and PTE. Recently fibrinogen
Aa Thr312Ala polymorphism was shown to be related with
CTEPH [13] and PTE [14], and interestingly, Thr312Ala
polymorphism was associated with thicker fibrin fibers and more
extensive alpha-chain cross-linking [15].
In the present study, we screened the seven reported polymor-
phisms associated with CTEPH [13] from human subjects to




Between November 2006 and November 2010, 101 subjects
with CTEPH were analyzed. Between January 2008 and June
2010, 102 PTE subjects were analyzed. Of the PTE subjects, 58
were without evidence of chronic pulmonary hypertension at the
time of sampling and 44 were without pulmonary hypertension by
two years follow-up. 108 healthy controls (19 subjects with well-
controlled hypertension) with no history or evidence of venous
thromboembolism were also analyzed. All subjects were Han
Chinese and from Beijing Chao-Yang Hospital affiliated with the
Capital Medical University. The Ethics Committee of Beijing
Chao-Yang Hospital of Capital Medical University approved all
experimental procedures. An informed consent form was provided
according to the Declaration of Helsinki, and written informed
consent was obtained according to institutional guidelines from all
subjects. All subjects were evaluated according to a standardized
protocol, including clinical history, physical examination, labora-
tory tests and computed tomography of pulmonary angiography
(CTPA) or magnetic resonance pulmonary angiography (MRPA)
or ventilation/perfusion scan (V/Q scan), transthoracic echocar-
diography, ultrasound check of lower extremity when PTE or
CTEPH was suspected and right heart catheterization as
pulmonary hypertension was suspected. CTEPH and PTE were
diagnosed according to the corresponding guidelines. All PTE
subjects had received standard therapy for PTE consisting of one-
week unfractionated or low molecular weight heparin followed by
oral anticoagulation for at least six months.
Blood Sampling and Processing
Blood samples (2 ml) were drawn from veins, collected in
Vacutainer tubes containing sodium citrate and centrifugated
immediately at 3000 rpm for 15 minutes at room temperature.
0.5 ml aliquots of plasma and blood cells were stored at280uC for
further analysis.
Genomic DNA Extraction and Genotyping
Genomic DNA was extracted from blood cells by a genomic
DNA extraction kit from TIANGEN BIOTECH CO. LTD
(Beijing, China, catalog NO. DP304). Polymorphisms were
detected by MassArray (Sequenom, Bioyong Technologies Inc,
Beijing, China) or restriction fragment length polymorphism
(RFLP). Seven single nucleotide polymorphisms (SNPs) including
fibrinogen Aa Thr312Ala (rs6050), fibrinogen Bb Arg448Lys
(rs420), fibrinogen Bb 2148C/T (rs1800787), fibrinogen Bb
2455G/A (rs1800790), prothrombin 19911A/G (rs3136516),
plasminogen activator inhibitor-1 (PAI-1 4G/5G, rs1799768),
tissue plasminogen activator 7351C/T (t-PA, rs2020918) were
studied. Fibrinogen Aa Thr312Ala (rs6050), fibrinogen Bb 148C/
T (rs1800787) and fibrinogen Bb 455G/A (rs1800790) SNPs were
detected by RFLP, other polymorphisms were detected by
MassArray.
Fibrinogen Purification
Fibrinogen was purified using ethanol precipitation (details in
Protocol S1). The purity of the fibrinogen was assessed by
densitometry of Coomassie stained polyacrylamide gels after
electrophoresis under reducing conditions. The concentration of
the fibrinogen was determined by ultraviolet spectroscopy.
Fibrin Formation and Digestion with Plasmin
Fibrin clots were prepared in microcentrifuge tubes by
incubating thrombin (2 units/ml final concentration) with
fibrinogen (2 mg/ml final concentration) in 25 ml of forming
buffer [50 mM Tris (pH 7.4), 100 mM NaCl, and 20 mM
ethylenediaminetetraacetic acid] for 1 h at room temperature.
Plasmin [P1867, Sigma-Aldrich (Shanghai) Trading Co. Ltd] was
then added (50 ml of 25 mg/ml) for clot digestion for various time
Table 1. Clinical data of subjects.
CTEPH (n=101)
PTE
(n =102) Controls (n =108) p value
Age at first diagnosis, median [IQR] (years) 54.02612.9 [13–85] 58.33614.9 [18–84] 54.19616.55 [18–86] 0.065
Male, n (%) 61 (60.4) 53 (52) 46 (42.6) 0.036
Smoke*, n (%) 16 (15.8) 16 (15.7) 17 (15.7) 1
Operation or fracture within 1 month, n (%) 0 (0) 22 (21.6) 0 (0) ,0.001
Cardiovascular disease history, n (%) 28 (27.7) 52 (51) 19 (17.6) ,0.001
Pulmonary arterial pressure (mmHg) [IQR] (n) 52612.54 [27–89] (81) ,25 ,25
Pulmonary vascular resistance (dyn.sec/cm5) [IQR] (n) 1091.046483.14 [242–3262]
(75)
,100 ,100
Cardiac index (L/min/cm2) [IQR] (n) 3.561.14 [1.25–6.9] (75) – –
Basic characteristic and risk factors for patients. Data are reported as number (%) or median (IQR, interquartile range); P-values were calculated by univariable analysis
(x2-test).
Note: *smoke : smoke$300 cigarettes each year, and smoke within one month when enrolled.
doi:10.1371/journal.pone.0069635.t001
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periods (0 h, 1 h, 3 h, 6 h and 12 h) at 37uC. The digestion
reaction was then terminated and samples heated at 95uC for 5
minutes and stored at 220uC.
Electrophoretic Analysis of Fibrin
Aliquots of plasmin-digested samples (equivalent to 5 mg of
fibrin) were assessed using sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) (10% polyacrylamide gels). Band
intensities of Coomassie-stained gels were scanned and analyzed
by Image J software (Version 2.1). Data were normalized to the
band intensity of the undigested control (0 h).
Statistical Analysis
Genotype and allele frequencies were calculated for each locus.
Observed frequencies in all groups were compared with those
predicted by the Hardy-Weinberg equilibrium equation using the
Chi-squared test. Any SNP deviated significantly from Hardy-
Weinberg equilibrium was excluded for statistic analysis. Geno-
type and allele frequencies were analyzed using the Chi-squared
test, or Fisher’s exact test in the case of low numbers. The risk of
disease associated with each genotype was estimated by logistic
regression analysis, where SNP genotype was coded in a three-
level fashion, i.e. most rare homozygous genotype, heterozygous
genotype and most common homozygous genotype, with the latter
being the reference category. All analyses were repeated using
multiple logistic regression models that adjusted for any index
within the basic demographic or risk factors with differences
between groups. P value of less than 0.05 was considered
statistically significant and P value of less than 0.01 was considered
highly significant. All statistics were performed using SPSS 13.0
software.
Results
Clinical Data of Subjects
Polymorphisms are associated with CTEPH or PTE. Therefore,
CTEPH and PTE patients were analyzed in the present
investigation. 101 CTEPH subjects, 102 PTE subjects and 108
healthy controls were analyzed and the clinical data are shown in
Table 1. The average age at first diagnosis was similar in the three
groups, but the male/female ratio was higher in CTEPH group
(62%). Percentage of subjects with smoking history was similar in
three groups, but the percentages of subjects with the history of
operation or fracture within one month were higher in PTE group.
Though history of cardiovascular diseases differed between three
groups, most subjects had well-controlled hypertension, only four
subjects from the PTE group and six subjects from the CTEPH
group were diagnosed with coronary artery disease (CAD). No
subject had a history of cancer.
Genotype Polymorphism Frequencies and Allele
Frequencies
Although polymorphisms are associated with CTEPH or PTE,
no polymorphism was reported to be involved in CTEPH but not
PTE. Since fibrin resistance has been suggested to be associated
with CTEPH, polymorphisms possibly associated with fibrin
resistance of the collected subjects were analyzed (Table 2 and
Table S1). No significant deviation from Hardy-Weinberg
equilibrium was observed in any polymorphism and group. The
genotype frequencies of fibrinogen Bb Arg448Lys, fibrinogen Bb
2148C/T, fibrinogen Bb 2455G/A, prothrombin 19911A/G,
PAI-1 4G/5G, t-PA 7351C/T did not differ between the groups.
Interestingly, differences of the genotype frequency (P=0.034) and
allele frequency (P=0.01) of fibrinogen Aa Thr312Ala (A/G) were
observed in different groups. There was significant difference in
frequencies of genotype and allele gene between CTEPH subjects,
controls (genotype frequencies: P=0.017, allele frequencies:
P=0.005) and PTE subjects (genotype frequencies: P=0.044,
allele frequencies: P=0.018), but there was no statistical difference
between PTE subjects and controls in respect to frequencies of
genotype and allele gene (genotype frequencies: P=0.654, allele
frequencies: P=0.691). Logistic regression analysis confirmed that
fibrinogen Aa Thr312Ala (A/G) increased the incidence of
Table 2. Genotype and allele frequencies of the Fibrinogen Aa Thr312Ala polymorphism.
Polymorphism Genotype/allele Frequency p value
CTEPH PTE Control Between 3 groups Between 2 groups
Aa Thr312Ala (A/G)
rs6050
A/A 25%(25/100) 37%(37/99) 43%(45/106) P=0.034 CTEPH/control
0.017
A/G 57%(57/100) 55%(54/99) 48%(51/106) PTE/control 0.654
G/G 18%(18/100) 8%(8/99) 9%(10/106) CTEPH/PTE 0.044
A 55%(109/200) 64%(128/198) 67%(141/212) P=0.01 CTEPH/control
0.005
G 45%(95/200) 35%(70/198) 33%(71/212) PTE/control 0.691
CTEPH/PTE 0.018
All frequencies are presented as % (n/total sample number). Genotype and allele frequencies were analyzed using the Chi-squared test, or Fisher’s exact test in the case
of low numbers. CTEPH: chronic thromboembolic pulmonary hypertension; PTE: pulmonary thromboembolism. Thr: threonine; Ala alanine;
doi:10.1371/journal.pone.0069635.t002
Table 3. Odd ratios and 95% CI of fibrinogen Aa Thr312Ala in
CTEPH, PTE and controls.
Group
Adjusted P
value OR Adjusted OR
Adjusted 95%
CI
PTE/control 0.444 1.086 1.218 0.736–2.015
CTEPH/control 0.004 1.763 2.037 1.262–3.289
CTEPH/PTE 0.058 1.623 1.625 0.983–2.686
Odd ratios (OR) and 95% confidence interval (95%CI) of fibrinogen Aa
Thr312Ala in CTEPH, PTE and controls. OR and 95%CI of fibrinogen Aa
Thr312Ala to CTEPH and PTE before and after adjustment of age, sex, smoke,
operation or fracture history within 1 month and cardiovascular disease history.
All OR and 95%CI are calculated by multiple logistic regression models.
doi:10.1371/journal.pone.0069635.t003
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CTEPH compared with that of the controls (OR=1.763 95%CI:
1.185–2.623) and PTE (OR=1.623, 95%CI: 1.087–2.426)
(Table 3).
Fibrinogen Aa Thr312Ala (A/G) is an Independent Risk
Factor for CTEPH, but not PTE
The effects of fibrinogen Aa Thr312Ala (A/G) on CTEPH and
PTE were further analyzed with adjustment of the demographic
differences between the groups (Table 3). The adjusted OR (2.037)
and 95% CI (1.262–3.289) showed that fibrinogen Aa Thr312Ala
(A/G) was an independent risk factor of CTEPH but not PTE
after adjustments of age, sex, smoking status, operation or fracture
history within 1 month and cardiovascular disease history in
multiple logistic regression analysis (Table 3).
Fibrin Derived from Subjects with CTEPH is More
Resistant to Lysis than that of PTE or Controls
Plasmin-mediated fibrin degradation from CTEPH subjects,
PTE subjects and controls was compared. The decline of fibrin
over time was calculated, which was significantly decreased in
CTEPH subjects in comparison with controls and PTE subjects,
implying that fibrin derived from CTEPH subjects is much
resistant to lysis (Fig. 1 and Fig. 2). However, there was no
significant difference between PTE subjects and controls (Fig.1
and Fig. 2). In one hour to twelve hours, the fibrin alpha chain
Figure 1. Plasmin-mediated cleavage of fibrin polymers from human subjects. Fibrin polymers from control (left), PTE (middle) and CTEPH
(right) subjects were analyzed for fibrin cleavage following plasmin treatment at the indicated time points. Samples were resolved by 10% SDS-PAGE
and proteins indicated by Coomassie blue staining. The bands near 72 kD, 55 kD, and just below the 55 kD marker represent alpha, beta, and gamma
chains of fibrin, respectively.
doi:10.1371/journal.pone.0069635.g001
Figure 2. Fibrin a chain digestion curve of control, PTE, and CTEPH groups. (A) The band intensity of the stained gels was quantified by
densitometry with Image J software and the corresponding data plotted as a function of time. The black solid line, gray solid line and gray dash line
represent control, PTE, and CTEPH subjects, respectively. (B) Decline rate of fibrin alpha in control, PTE and CTEPH groups. P value of fibrin alpha
digestion curves between control, PTE and CTEPH. P values are calculated by repeated measurement of categorical data. (C) Relative band intensity of
fibrin a chain in different time of three groups. Data are presented as ratio of band intensity to time at 0 h and are reported as mean6SEM. P value
was calculated v.s. control (*) or PTE (#) by repeated measurement of categorical data.
doi:10.1371/journal.pone.0069635.g002
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band intensity decreased in different degrees from different groups
(Fig. 2). Similar results were observed in fibrin beta chain and
fibrin gamma chain from different groups (data not shown).
Fibrin Resistance and Fibrinogen Aa Ala312Ala (G/G)
Genotype
The relationship between fibrin degradation and fibrinogen Aa
Thr312Ala (A/G) genotypes in CTEPH subjects was also studied,
and results demonstrated that there were differences between
different fibrinogen Aa Thr312Ala (A/G) genotypes and fibrin
resistance (Fig. 3 and Fig. 4). In one hour to twelve hours, the
fibrin alpha chain band intensity decreased in different degree in
different groups (Fig. 4).
Discussion
For the first time, we report a specific polymorphism responsible
for CTEPH but not PTE in Chinese patients. Our data shows that
fibrinogen Aa Thr312Ala polymorphism is an independent risk
factor of CTEPH due to fibrin resistance to lysis by plasmin and
the fact that it is related to the fibrinogen Aa Thr312Ala genotypes
in CTEPH patients.
Indeed, CTEPH is usually considered as a consequence of acute
PTE [7,16], and a recent study showed that CTEPH generally
Figure 3. Plasmin-mediated cleavage of fibrin polymers of different genotypes from CTEPH subjects. Fibrin polymers from A/A (left), A/
G (middle) and G/G (right) Aa Thr312Thr genotypes were analyzed for fibrin cleavage following plasmin treatment at the indicated time points.
Samples were resolved by 10% SDS-PAGE and proteins indicated by Coomassie blue staining. The bands near 72 kD, 55 kD, and just below the 55 kD
marker represent alpha, beta, and gamma chains of fibrin, respectively.
doi:10.1371/journal.pone.0069635.g003
Figure 4. Fibrin a chain digestion curve of different genotypes from CTEPH patients. (A) The band intensity of the stained gels was
quantified by densitometry with Image J software and the corresponding data plotted as a function of time. The black solid line, gray solid line and
gray dash line represent A/A, A/G, and G/G genotypes, respectively. (B) Decline rate of fibrin alpha chain with different genotypes from CTEPH groups.
P value of fibrin alpha digestion curves between different genotypes of fibrinogen Aa Thr312Ala in CTEPH groups. P values are calculated by repeated
measurement of categorical data. GG: fibrinogen Aa Thr312Ala (GG) genotype; GA: fibrinogen Aa Thr312Ala (GA) genotype; AA: fibrinogen Aa
Thr312Ala (AA) genotype. (C) Relative band intensity of fibrin a chain with different genotypes from CTEPH group. Data are presented as ratio of band
intensity to time at 0 h and are reported as mean 6 SEM. P value was calculated v.s. control (*) or PTE (#) by repeated measurement of categorical
data.
doi:10.1371/journal.pone.0069635.g004
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develops after acute PTE within a shorter period [17]. Therefore,
closer monitoring of high-risk cases is particularly important in
early diagnosis and treatment.
Previously, a case control study with 214 CTEPH subjects
found that fibrinogen Aa Thr312Ala polymorphism is associated
with CTEPH, but the study did not include a group of PTE
subjects [13]. In total, 45 subjects with acute PTE enrolled before
2008 have been followed up, and we excluded 1 subject when
CTEPH occurred. This CTEPH incidence from acute PTE is
consistent with the previous report of 0.5–3.8% [18,19]. Interest-
ingly, we found that fibrinogen Aa Thr312Ala polymorphism is
associated with CTEPH but not PTE as an independent risk factor
(Table 3). This study also suggested a potential difference of
fibrinogen Aa Thr312Ala polymorphism between CTEPH and
PTE (P=0.058) (Table 3).
Genotypes and allele frequencies of other previously reported
polymorphisms that associated with thrombotic diseases [fibrino-
gen Bb Arg448Lys (rs420), fibrinogen Bb 2148C/T (rs1800787),
fibrinogen Bb 2455G/A (rs1800790), prothrombin 19911A/G
(rs3136516), plasminogen activator inhibitor-1 (PAI-1 4G/5G,
rs1799768), tissue plasminogen activator 7351C/T (t-PA,
rs2020918)] did not show a difference between CTEPH and
control/PTE [20 21]. Nonetheless, our results are in line with a
large cohort study, which suggested only fibrinogen Aa Thr312Ala
polymorphism is associated with CTEPH among the common
polymorphisms in haemostatic or fibrolysis system [13].
Since increased fibrinogen levels have been reported to be
associated with risk for venous thrombosis [22], we investigated
whether fibrinogen Aa Thr312Ala (A/G) was associated with
plasma levels of fibrinogen in these three groups. However, there is
no obvious difference of fibrinogen levels between three genotypes,
and after adjustment of age, sex, smoking status, operation or
fracture history within 1 month and cardiovascular disease history
in multiple logistic regression analysis, the difference is not
significant (data not shown). This result is in accordance with
previous report [23] which also showed that fibrinogen Aa
Thr312Ala (A/G) was not associated with fibrinogen level.
Linkage disequilibrium (LD) has been shown for fibrinogen Aa
Thr312Ala (A/G) polymorphism and the haplotype of the
fibrinogen gamma gene, FGG-H2, which associates with reduced
fibrinogen gamma prime levels (c’). Further, it has been reported
that reduced fibrinogen c’ is an independent risk factor for venous
thrombosis [23,24], so this aspect maybe one of the mechanisms of
fibrinogen Aa Thr312Ala (A/G) polymorphism to CTEPH. But as
PTE also belongs to venous thrombosis, this hypothesis can not
fully explain the mechanism of fibrinogen Thr312Ala (A/G)
polymorphism.
Fibrin clots of patients with CTEPH were much resistant to
fibrolysis than that of healthy control subjects [9]. Fibrin derived
from subjects with CTEPH and pulmonary hypertension other
than thromboembolic [10] was reported to be resistant to lysis.
Fibrin resistance occurred in a smaller extent in subjects with prior
PTE with no hypertension [10]. Our data show fibrin from
CTEPH subjects was more resistant to lysis as compared to both
healthy controls and PTE subjects without pulmonary hyperten-
sion (Figure 1 and 2). The latter conclusion is slightly different
from that of the previous report [25]. The reason might be that the
diversiform influencing factors of fibrin resistance to lysis [25] such
as post-translational modifications [26] other than genetic
polymorphisms.
Genetic mutation and polymorphisms contribute to the
structure of the fibrin clot[27–29]. Ala312 fibrin clots have thicker
fibers and more extensive a–chain cross-linking than that of
Thr312 [15]. It is possible that the substitution of threonine to
alanine at position 312 of the C-terminal a-chain enhances lateral
aggregation leading to thicker fibers, consistent with the role of the
aC domains in lateral aggregation [30]. We tried to find the
possible relationship between the fibrin alpha chain degradation
rate and the genotypes of fibrinogen FGA (A gene that encodes for
the fibrinogen alpha chain) Thr312Ala (A/G) polymorphism in
CTEPH subjects. We found that fibrin with FGA GG genotype
(which encode fibrinogen with Ala312Ala) is more resistant than
the fibrin with FGA AG genotype (which encode fibrinogen with
Thr312Ala) or FGA AA genotype (which encode fibrinogen with
Thr312Thr) genotype. The low frequency of FGA GG genotypes
and some limitations in sample collection did not allow us to
properly assess the degradation rate of the fibrin alpha chain
between different genotypes of FGA Thr312Ala (A/G) polymor-
phism from the PTE subjects and controls. However, we
compared the lysis curve of CTEPH with fibrinogen Thr312Ala
AG and AA genotypes with the total lysis curve of PTE subjects
(with fibrinogen Thr312Ala AG and AA genotypes) or controls
(with fibrinogen Thr312Ala AG and AA genotypes) and found no
significant difference (P=0.086), further supporting the hypotheses
that the resistance of fibrin in CTEPH patients is mainly
determined by GG genotype.
Our study suggests that fibrinogen Aa Thr312Ala polymor-
phism is a potential biomarker in identifying CTEPH from acute
PTE. However, the sample size in this study may limit our power
in identifying other factors that influence the fibrin structure and
its resistance to lysis [31]. Further in vitro and in vivo functional
assessments are needed to determine the genetic effect of
Thr312Ala polymorphism on fibrinogen structure and function.
Our results demonstrate that fibrinogen Aa Thr312Ala polymor-
phism may contribute to chronic thromboembolic pulmonary
hypertension through increasing fibrin resistance, implying that
PTE subjects with fibrinogen Aa Ala312Ala genotype in clinic
may need long-term anticoagulation therapy.
Supporting Information
Table S1 Genotype and allele polymorphism frequen-
cies. Genotype and allele frequencies of the polymorphisms
detected. All frequencies are presented as % (n/total sample
number). Any SNP deviated significantly from Hardy-Weinberg
equilibrium was excluded for statistic analysis. Genotype and allele
frequencies were analyzed using the Chi-squared test, or Fisher’s
exact test in the case of low numbers. CTEPH: chronic
thromboembolic pulmonary hypertension; PTE: pulmonary
thromboembolism. t-PA: tissue plasminogen activator; PAI:
plasminogen activator inhibitor; Thr: threonine; Ala alanine;
Arg: arginine; Lys: lysine.
(DOC)
Protocol S1 Method of fibrinogen purification by etha-
nol precipitation. Fibrinogen was purified using an ethanol
precipitation method as follows: Place 1 ml plasma in ice water
bath, using a plastic stick stir in 0.215 ml solution ‘‘A’’ [1 ml 95%
EtOH+1 ml 55 mM NaCit (sodium citrate) pH7.0]. Adding the
solution in a drop wise fashion while cooling to 23uC. Let stand
for 15 minutes. Centrifuge at 23uC at 3500 rpm for 20 minutes.
Pipette off supernatant and discard. Add 0.55 ml Solution ‘‘B’’
(480 ml 95% EtOH +5.52 ml 0.055 M NaCit pH6.4) and stir for
10 minutes at 23uC as the protein sticks to the plastic stick at this
step. Centrifuge at 23uC at 3500 rpm for 10 minutes. Pipette off
supernatant and discard. Add 0.275 ml Solution ‘‘C’’ (0.055 M
NaCit pH6.4) at room temperature to dissolve precipitate fully by
gently shaking tube for about 20 minutes, try not to make bubbles.
Place tube in ice water bath, add 0.0475 ml Solution ‘‘D’’ (96 ml
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Absolute EtOH +632 ml NaCit pH6.4). Centrifuge at 23uC at
3500 rpm for 10 minutes. Remove supernatant and save it, this
contains the fibrinogen, discard the pellet. Add 0.14 ml Solution
‘‘E’’ (283 ml Absolute EtOH +1 ml 0.055 M NaCit pH6.4) drop
wise to supernatant while stirring at 23uC, then let sit for 10
minutes at 23uC. Centrifuge at 23uC at 3500 rpm for 15
minutes. Discard supernatant. Re-dissolve in 0.25 ml Solution ‘‘F’’
(20 mM NaCit, 150 mM NaCl, pH 7.0) and make sure all the
small particles are dissolved.
(DOC)
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